Last reviewed · How we verify

sclerotherapy with aethoxysclerol foam

Medical University of Vienna · FDA-approved active Small molecule

Aethoxysclerol foam causes endothelial damage and thrombosis within varicose veins, leading to vessel fibrosis and obliteration.

Aethoxysclerol foam causes endothelial damage and thrombosis within varicose veins, leading to vessel fibrosis and obliteration. Used for Varicose veins of the lower extremities, Venous insufficiency.

At a glance

Generic namesclerotherapy with aethoxysclerol foam
SponsorMedical University of Vienna
Drug classSclerosing agent
ModalitySmall molecule
Therapeutic areaVascular/Dermatology
PhaseFDA-approved

Mechanism of action

Aethoxysclerol is a sclerosing agent that, when injected as a foam into varicose veins, damages the venous endothelium and triggers an inflammatory response. This results in thrombosis and subsequent fibrosis of the vessel wall, causing the vein to close and be reabsorbed by the body. The foam formulation increases contact surface area with the endothelium, enhancing efficacy compared to liquid formulations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: